These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33508971)

  • 1. Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: A comparative study.
    Manayath G; Verghese S; Ranjan R; Agrawal H; Khanna A; Narendran V; Chhablani J
    Eur J Ophthalmol; 2021 Nov; 31(6):3110-3116. PubMed ID: 33508971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK; Kim K; Kim ES; Yu SY
    Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy Patients.
    Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Schlingemann RO; Hoyng CB; Boon CJF
    Ophthalmol Retina; 2022 Oct; 6(10):930-938. PubMed ID: 35470085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled Trial.
    van Rijssen TJ; van Dijk EHC; Tsonaka R; Feenstra HMA; Dijkman G; Peters PJH; Diederen RMH; Hoyng CB; Schlingemann RO; Boon CJF
    Am J Ophthalmol; 2022 Jan; 233():101-110. PubMed ID: 34214454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of low-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Leys E; Tuttle S; Rasquin F; Neu F; Postelmans L
    J Fr Ophtalmol; 2015 Oct; 38(8):709-16. PubMed ID: 26345542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
    Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Retinochoroidal Vascular and Structural Changes after Half-Dose Photodynamic Therapy versus Half-Fluence Photodynamic Therapy Based on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
    Karasu B; Akbas YB; Aykut A; Celebi ARC
    Ophthalmologica; 2022; 245(4):323-334. PubMed ID: 35249031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
    Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy.
    Altinel MG; Kanra AY; Totuk OMG; Ardagil A; Kabadayi K
    Photodiagnosis Photodyn Ther; 2021 Mar; 33():102081. PubMed ID: 33157327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
    Arevalo JF; Espinoza JV
    Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
    Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
    Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
    Hayashida M; Miki A; Honda S; Nakamura M
    Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF
    Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Noh SR; Kang MS; Kim K; Kim ES; Yu SY
    Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.
    Kim YK; Ryoo NK; Woo SJ; Park KH
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2063-73. PubMed ID: 25616728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy.
    Park DG; Jeong S; Noh D; Sagong M
    Br J Ophthalmol; 2021 Jun; 105(6):844-849. PubMed ID: 32727733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3.
    Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Hoyng CB; Schlingemann RO; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2023 Mar; 261(3):659-668. PubMed ID: 36202933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.